Fig. 1: HER2 assessment in 548 cervical cancer patients. | npj Precision Oncology

Fig. 1: HER2 assessment in 548 cervical cancer patients.

From: HER2 expression in cervical squamous cell carcinoma: high prevalence of HER2-low/ultralow and spatiotemporal heterogeneity across tumor evolution

Fig. 1: HER2 assessment in 548 cervical cancer patients.

A HER2 testing process and results: HER2-null accounted for 24.4%, HER2-ultralow for 32.5%, HER2-low for 39.6%, and HER2-positive for 3.5%. B HER2 2+ cases showed positive FISH testing. C HER2 immunohistochemistry: HER2-null, HER2-ultralow, HER2 1+, HER2 2+, and HER2 3+. D HER2 expression was significantly higher in poorly differentiated cervical squamous cell carcinoma (CSCC) compared to well-to-moderately differentiated cases (p = 0.02).

Back to article page